Nanfang Hospital, Southern Medical University
This is a single arm, open-label, prospective clinical trial to evaluate the combination of neoadjuvant short-course radiotherapy and toripalimab (PD-1 antibody) for locally advanced rectal cancer (LARC) patients with high risk factors. A total of 53patients will be enrolled in this trial to receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody. Then they will receive the TME surgery and another 2 cycles of CAPOX chemotherapy. The primary end point is the rate of pathological complete response (pCR). The long-term prognosis and adverse effects will also be evaluated and analyzed.
Locally Advanced
High-Risk
Rectal Cancer
MSS
Toripalimab
short-term radiotherapy
Oxaliplatin
Capecitabine
Not Applicable
Study Type : | Interventional |
Estimated Enrollment : | 53 participants |
Masking : | None (Open Label) |
Primary Purpose : | Treatment |
Official Title : | Toripalimab Combined With Neoadjuvant Chemoradiotherapy as First-line Treatment for Locally Advanced,High-Risk,MSS Rectal Cancer |
Actual Study Start Date : | July 1, 2023 |
Estimated Primary Completion Date : | January 1, 2025 |
Estimated Study Completion Date : | August 1, 2026 |
Arm | Intervention/treatment |
---|---|
Experimental: short-course radiotherapy plus chemotherapy and immunotherapy A total of 53 patients receive 5*5Gy short-course radiotherapy, followed by 4 cycles of CAPOX chemotherapy and PD-1 antibody, finally receive the TME surgery and another 2 cycles of CAPOX chemotherapy. |
Drug: Toripalimab Radiation: short-term radiotherapy Drug: Oxaliplatin Drug: Capecitabine |
Ages Eligible for Study: | 18 Years to 75 Years |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Recruiting
Nanfang Hospital Southern Medical University
Guangzhou, Guangdong, China, 510000